Volume 153, Issue 4, Pages (April 2018)

Slides:

Advertisements

Similar presentations

COPD Management of Stable COPD Shyam Rao May 2014.

Advertisements

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

Volume 129, Issue 3, Pages (March 2006)

Kanazawa Hiroshi , MD, Hirata Kazuto , MD, Yoshikawa Junichi , MD

Tell-tale Telangiectasias

Bronchial Hyperresponsiveness in the Assessment of Asthma Control

Bronchial Hyperresponsiveness in the Assessment of Asthma Control

Colloquium on Therapy of Right Heart Failure

Volume 151, Issue 1, Pages (January 2017)

When to Be Rash About a Fever and Headache

Volume 56, Issue 1, Pages (July 1969)

Volume 128, Issue 2, Pages (August 2005)

Epidemiology and Treatment of Lung Cancer in Seattle

Bovine Tuberculosis Eradication

Hyperbaric Oxygenation in Cardiac and Pulmonary Disease

Volume 128, Issue 3, Pages (September 2005)

Volume 121, Issue 4, Pages (April 2002)

The Salmeterol Multicenter Asthma Research Trial

Air Pollution and Chest Disease

Antonio Anzueto, MD, Marc Miravitlles, MD CHEST

The ABCs of Asthma Control

The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control Barbara P. Yawn, MD, MSc Mayo Clinic Proceedings

The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD

The Therapeutic Potential of Hyaluronan in COPD

What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?

Volume 153, Issue 4, Pages (April 2018)

When Would You Use Single Inhaler Triple Therapy in COPD?

Severe Asthma in Primary Care: Identification and Management

Zaid J. Yaqoob, MD, Sadeer G. Al-Kindi, MD, Joe G. Zein, MD CHEST

Blood eosinophils as a marker of eosinophilic exacerbations in COPD

Acute Pulmonary Exacerbations of Sarcoidosis

Precision Medicine Urgency

Andrew J. Simpson, PhD, Stephen J. Fowler, MD CHEST

Has the 6-Min Walk Distance Run Its Course?

Volume 147, Issue 4, Pages (April 2015)

Prevention of Acute Exacerbations of COPD

Apnea in the Nonobese CHEST Volume 153, Issue 4, (April 2018)

Evidence-Based Asthma Guidelines

Counterpoint: Should All ICU Patients Receive Continuous Sedation? No

Imaging for the Management of Community-Acquired Pneumonia

Michael E. Wechsler, MD Mayo Clinic Proceedings

Possible Role of Statins in COPD-Related Pulmonary Hypertension

POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management

A Patient With Chest Pain and Hyperacute T Waves

Economic Burden of COPD in the Presence of Comorbidities

Volume 154, Issue 6, Pages (December 2018)

COUNTERPOINT: Is It Time for Pulmonary Concierge Practices? Not Yet

Volume 155, Issue 1, Pages e1-e4 (January 2019)

Pinja Ilmarinen, PhD, Leena E

Bedside Calibration Of Pulmonary Artery Catheters

A 7-Year-Old Boy With Sudden Onset of Loud Snoring

Volume 151, Issue 4, Pages (April 2017)

A Man in His 70s Presenting With Chest Pain and Hematuria

Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.

Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices. Benefit–risk balance.

Volume 42, Issue 2, Pages (August 1962)

Calcification of the Coronary Artery

Volume 150, Issue 4, Pages (October 2016)

Sean Connolly, MD, Peter Hountras, MD CHEST

Craig Fryman, MD, Sahar Ahmad, MD CHEST

Infective Exacerbations of COPD

POINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? Yes

Ipratropium Bromide Bronchodilator Solution

COPD Guidelines: A Review of the 2018 GOLD Report

New Members of the Editorial Board

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

Rebuttal From Dr Kollef

John Reid, MD, Donald Cockcroft, MD CHEST

Choosing inhaler therapy for patients with stable COPD based on the Global Initiative for Chronic Obstructive Lung Disease grouping. Choosing inhaler therapy.

Presentation transcript:

Volume 153, Issue 4, Pages 782-784 (April 2018) COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV1 < 50% Predicted) COPD? No Ian D. Pavord, FMedSci CHEST Volume 153, Issue 4, Pages 782-784 (April 2018) DOI: 10.1016/j.chest.2018.01.030 Copyright © 2018 American College of Chest Physicians Terms and Conditions

Figure 1 Proposed management of COPD incorporating two major treatable traits: symptoms due to airflow limitation and risk assessed using the blood eosinophil count. Risk refers to future risk of exacerbation and decline in FEV1. Treatments with a trait-specific effect are included. Rescue short-acting bronchodilators (SABA or SAMA) could be used in all situations and patient categories, as required. ICS = inhaled corticosteroid; CS = corticosteroid; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist; PRN = as needed; SABA = short-acting β2-agonist; SAMA = short-acting muscarinic antagonist. CHEST 2018 153, 782-784DOI: (10.1016/j.chest.2018.01.030) Copyright © 2018 American College of Chest Physicians Terms and Conditions